These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

140 related items for PubMed ID: 6405117

  • 1. The use of prostaglandins and prostaglandin inhibitors in critically ill neonates.
    Cohen MA.
    MCN Am J Matern Child Nurs; 1983; 8(3):194-9. PubMed ID: 6405117
    [No Abstract] [Full Text] [Related]

  • 2. Clinical use of prostaglandins and prostaglandin synthetase inhibitors in cardiac problems of the newborn.
    Olley PM, Coceani F, Rowe RD, Swyer PR.
    Adv Prostaglandin Thromboxane Res; 1980; 7():913-6. PubMed ID: 6768235
    [No Abstract] [Full Text] [Related]

  • 3. Medical treatment of the ductus arteriosus.
    Rudolph AM, Heymann MA.
    Hosp Pract; 1977 Feb; 12(2):57-65. PubMed ID: 557025
    [Abstract] [Full Text] [Related]

  • 4. Congenital heart disease and respiratory distress syndrome. Reversal of indomethacin closure of patent ductus arteriosus by prostaglandin therapy in a preterm infant.
    Strauss A, Modanlou HD, Gyepes M, Wittner R.
    Am J Dis Child; 1982 Oct; 136(10):934-6. PubMed ID: 6889810
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Patent ductus arteriosus in the neonate.
    Gersony WM.
    Pediatr Clin North Am; 1986 Jun; 33(3):545-60. PubMed ID: 3520463
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Prostaglandins and the management of congenital heart disease.
    Taylor WJ, Alpert BS.
    Am Fam Physician; 1982 Dec; 26(6):127-32. PubMed ID: 6890758
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [Long-term treatment using prostaglandin E2 in congenital heart defects with the pulmonary circulation being supplied by a patent ductus arteriosus].
    Hruda J, Samánek M, First T, Vorísková M, Skovránek J.
    Cesk Pediatr; 1985 May; 40(5):257-62. PubMed ID: 3860302
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Morphologic features of the ductus arteriosus after prostaglandin E1 administration for ductus-dependent congenital heart defects.
    Park IS, Nihill MR, Titus JL.
    J Am Coll Cardiol; 1983 Feb; 1(2 Pt 1):471-5. PubMed ID: 6681824
    [No Abstract] [Full Text] [Related]

  • 16. Risk factors for persistent ductus arteriosus patency during indomethacin treatment.
    Chorne N, Jegatheesan P, Lin E, Shi R, Clyman RI.
    J Pediatr; 2007 Dec; 151(6):629-34. PubMed ID: 18035143
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Prolonged prostaglandin E-1 therapy of newborn infants with congenital heart defects].
    Kertész E, Hencz P, Tekulics P, Beviz J, Száva J, Matkó I, Kovács G.
    Orv Hetil; 1980 May 18; 121(20):1197-9. PubMed ID: 7413203
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.